Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab versus secukinumab for juvenile idiopathic arthritis-associated uveitis or chronic anterior uveitis
ISRCTN12427150Phase 2Active, not recruiting
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of adalimumab and secukinumab in juvenile idiopathic arthritis-associated uveitis (JIA-U) and cyclitis (3 arms), sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoints: Stage 1 primary endpoint and Stage 2 primary endpoint. Started Mar 2023; status: active, not recruiting.
02
Drugs
adalimumabsecukinumab
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)cyclitis
Beyond the preview
Go deeper on ISRCTN12427150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12427150.